Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 906

Sort by

Sort Order Select

Journal Articles

Aberrant Responsiveness of Erythropoiesis to Iron Deficiency in Polycythemia Vera

Maria Feola, PhD, Daniel Moskop, Nada Terra, Young C. Park, Andrew Dunbar, MD, Ross L. Levine, MD, Ronald Hoffman, MD, Yelena Ginzburg, MD

Blood (2019) 134 (Supplement_1): 429.

https://doi.org/10.1182/blood-2019-131095

Published: 2019

Journal Articles

Randomized Controlled Trial of the Efficacy and Safety of Deferiprone in Iron-Overloaded Patients with Sickle Cell Disease or Other Anemias

Blood (2019) 134 (Supplement_1): 618.

https://doi.org/10.1182/blood-2019-122062

Published: 2019

Journal Articles

A Pilot Study of Exjade (Deferasirox) As Monotherapy in Higher Risk MDS or Acute Myeloid Leukemia

James K. Mangan, MD PhD, Imran Ajmal, MBBS, Noelle V. Frey, MD, Elizabeth O. Hexner, MD, Alison W. Loren, MD MSCE, Martin Carroll, MD, Selina M. Luger, MD FRCPC

Blood (2019) 134 (Supplement_1): 5155.

https://doi.org/10.1182/blood-2019-131668

Published: 2019

Journal Articles

Impact of HFE gene Variants on Iron Overload, Overall Survival and Leukemia-Free Survival in Myelodysplastic Syndromes

Mathias A. Schneeweiss, Greiner Georg, MD PhD, Susanne Herndlhofer, Julia Schellnegger, Maria-Theresa Krauth, MD, Friedrich Wimazal, MD, Corinna Steinhauser, Renate Thalhammer, MD, Ilse Schwarzinger, MD, Harald Esterbauer, MD PhD, Manuela Födinger, Peter Valent, MD, Wolfgang R. Sperr, MD

Blood (2019) 134 (Supplement_1): 4269.

https://doi.org/10.1182/blood-2019-123390

Published: 2019

Journal Articles

A Multicenter, Italian Trial of Early Iron Chelation Therapy with Low Dose Deferasirox (Exjade®) in Patients with Low/Intermediate-1 Risk MDS at the Beginning of Transfusional Story

Emanuele Angelucci, MD, Mario Capasso, PhD, Matteo Giovanni Della Porta, MD, Gian Luca Forni, Domenico Girelli, MD, PhD, Esther Natalie Oliva, MD, Federica Pilo, MD, Marino Clavio, MD, Marta Riva, MD, Annamaria Pelizzari, MD, Pasquale Niscola, MD PhD, Daniela Cilloni, MD PhD, Gianni Binotto, MD, Elena Crisà, MD, Valeria Santini, MD

Blood (2019) 134 (Supplement_1): 4256.

https://doi.org/10.1182/blood-2019-125575

Published: 2019

Journal Articles

Hematopoietic Stem Cell Transplantation in Βthalassemia Major: The Egyptian Outcome

Amal El-Beshlawy, MD, Amina AbdelSalam, MD, Gamal Fathy, MD, Khaled M. Salamaa, MD, Mona El ghamrawy, MD, Samar S. Ramadan, M.Sc., Alaa M. Elhaddad, MD

Blood (2019) 134 (Supplement_1): 5732.

https://doi.org/10.1182/blood-2019-124398

Published: 2019

Journal Articles

Understanding the Association between Transfusion Status (TS) and Overall Survival (OS), and Other Clinical Outcomes in Patients with Myelodysplastic Syndromes (MDS) from the Physicians' Perspective: A Pilot Survey

Shaloo Gupta, Zhiyi Li, Thomas Schroeder, MD, Austin Kulasekararaj, MDMBBS,MRCP,FRCPath, Joana E. Matos, Alexandra Berk, Derek Tang, PhD BSPharm, Jay Grisolano

Blood (2019) 134 (Supplement_1): 5901.

https://doi.org/10.1182/blood-2019-122725

Published: 2019

Journal Articles

MRI Evaluation of Liver and Cardiac Iron Overload Impact on Hematopoietic Stem Cell Transplantation with β-Thalassemia Major

Libai Chen, MD, Yuelin He, MD, Jianyun Wen, Wenjing Yang, Xuan Liu, Yongsheng Ruan, MD, Xiaoqin Feng, Chunfu Li, MD, Xuedong Wu, MD PhD

Blood (2019) 134 (Supplement_1): 5738.

https://doi.org/10.1182/blood-2019-128903

Published: 2019

Journal Articles

Prevalence of Iron Deficiency and Iron Deficiency Anemia during Pregnancy: A Single Centre Canadian Study

Grace Tang, MSc, Andrea Lausman, MD FRCSC, Jameel Abdulrehman, MD, Jessica Petrucci, MSc, Rosane Nisenbaum, PhD, Lisa K. Hicks, MD MSc, Michelle Sholzberg, MDBSc,FRCPC,MSc

Blood (2019) 134 (Supplement_1): 3389.

https://doi.org/10.1182/blood-2019-127602

Published: 2019

Journal Articles

Risk Factors and Characteristics of CRS in CAR-T Treatment

Yan Zhiling, MD, Zhang Huanxin, MD, Ying Wang, Jiang Cao, MD, Jianlin Qiao, PhD, Deipeng Li, MD, Bin Pan, MD, Qingyun Wu, PhD, Zhenyu Li, MD, Kailin Xu, MD

Blood (2019) 134 (Supplement_1): 4462.

https://doi.org/10.1182/blood-2019-129777

Published: 2019

Journal Articles

NTBI Is Transiently Generated from Two Compartments during a Single Dose of Intravenous Iron - a Randomized Controlled Clinical Study

Maciej W Garbowski, MD PhD, Sukhvinder S Bansal, PhD, John B. Porter, MA MDFRCP FRCPath, Susanna Burckhardt, PhD, Robert Hider, PhD

Blood (2019) 134 (Supplement_1): 2234.

https://doi.org/10.1182/blood-2019-125618

Published: 2019

Journal Articles

Factor-Associated Risk Factors of Mild Cognitive Impairment in Thalassemia Patients : Probable Role of FGF21

Wasan Theerajangkhaphichai, MD, Adisak Tantiworawit, MD, Jirapas Sripetchwandee, PhD, Nattayaporn Apaijai, PhD, Sirawit Sriwichaiin, MD, Napatsorn Saiyasit, Kewarin Jinawong, Busarin Arunsak, Pokpong Piriyakhuntorn, MD, Thanawat Rattanathammethee, MD, Sasinee Hantrakool, MD, Chatree Chai-Adisaksopha, MD PhD, Ekarat Rattarittamrong, MD, Lalita Norasetthada, MD, Pimlak Charoenkwan, MD, Nipon Chattipakorn, MD PhD, Siriporn Chattipakorn, DDS, PhD

Blood (2019) 134 (Supplement_1): 2251.

https://doi.org/10.1182/blood-2019-125182

Published: 2019

Journal Articles

Effects of Luspatercept on Iron Overload and Impact on Responders to Luspatercept: Results from the BELIEVE Trial

John Porter, Maria Domenica Cappellini, MD, Thomas Coates, MD, Olivier Hermine, Vip Viprakasit, MD DPhil, Ersi Voskaridou, Hong Keng Liew, Silverio Perrotta, Abderrahim Khelif, Antonis Kattamis, Abderrahmane Laadem, Jeevan K. Shetty, Wen-Ling Kuo, Dimana Miteva, Tatiana Zinger, Peter G. Linde, Daniel Sinsimer, Ali Taher

Blood (2019) 134 (Supplement_1): 2245.

https://doi.org/10.1182/blood-2019-122561

Published: 2019

Journal Articles

Does Gene Therapy in Beta Thalassemia Normalize Novel Markers of Ineffective Erythropoiesis and Iron Homeostasis?

Alexis A. Thompson, MD MPH, Tomas Ganz, MD PhD, Mary Therese Forsyth, Elizabeta Nemeth, PhD, Sherif M. Badawy, MD

Blood (2019) 134 (Supplement_1): 816.

https://doi.org/10.1182/blood-2019-129658

Published: 2019

Journal Articles

Clinical Outcomes after Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Transfusion-Dependent β-Thalassemia Treated at the Bambino Gesù Children's Hospital, Rome, Italy

Pietro Merli, MD, Annalisa Ruggeri, MD, Mattia Algeri, MD, Giuseppina Li Pira, PhD, Giulia Ceglie, MD, Katiana Gruppioni, MPH, Sanjeev Kommera, MS, Jenfue Maa, PhD, Franco Locatelli, MD PhD

Blood (2019) 134 (Supplement_1): 969.

https://doi.org/10.1182/blood-2019-123440

Published: 2019

Journal Articles

Use of Buprenorphine/Naloxone in Ameliorating Acute Care Utilization and Chronic Opioid Use in Adults with Sickle Cell Disease

Ifeyinwa (ify) Osunkwo, MD MPH, Padmaja Veeramreddy, MD, Justin Arnall, PharmD, CPP, BCOP, Rachel Crawford, PharmD, BCPS, James T Symanowski, PhD, Rasaq Olaosebikan, MD MSc, Srinivasa Reddy Sanikommu, MD, Stephanie Newby, MD, Stephen Wyatt, DO, Jamie Sebaaly, Katherine Rector

Blood (2019) 134 (Supplement_1): 790.

https://doi.org/10.1182/blood-2019-126589

Published: 2019

Journal Articles

Treosulfan Metabolite (S, S-EBDM) Pharmacokinetics Influences Regimen Related Toxicity in Patients with Beta Thalassaemia Major Undergoing HSCT

Aswin Anand PAI, MSc, John C Panetta, PhD, Ezhil Pavai Mohanan, PhD, Raveen Stephen Stallon Illangeswaran, MSc, Balaji Balakrishnan, PhD, Eunice Sindhuvi Edison, PhD, Kavitha M Lakshmi, MSc, Uday Prakash Kulkarni, MD DM, Anup Joseph Devasia, MD DM, Fouzia N., Anu Korula, MD DM, Aby Abraham, MD DM, Biju George, MDDM, Vikram Mathews, MD DM, Alok Srivastava, MD,FRACP,FRCPA, Poonkuzhali Balasubramanian, PhD

Blood (2019) 134 (Supplement_1): 1977.

https://doi.org/10.1182/blood-2019-125604

Published: 2019

Journal Articles

Neurological Adverse Events Following CAR-T Cell Therapy: A Real-World Analysis of Adult Patients Treated with Axicabtagene Ciloleucel or Tisagenlecleucel

Ajeet Gajra, MD FACP, Marjorie E Zettler, PhD MPH, Eli G Phillips Jr., PharmD, JD, Andrew J Klink, PhD MPH, Jonathan K. Kish, PhD MPH, Sonam Mehta, Bruce Feinberg, DO

Blood (2019) 134 (Supplement_1): 1952.

https://doi.org/10.1182/blood-2019-129593

Published: 2019

Journal Articles

Routine Management, Healthcare Resource Use and Patient/Caregiver-Reported Outcomes of Patients with Transfusion-Dependent β-Thalassaemia in the United Kingdom: A Mixed Methods Observational Study

Farrukh Shah, MDMBBS,FRCPath, Paul Telfer, DM, FRCP, Mark Velangi, Shivan Pancham, Robert Wynn, Sally Pollard, Elizabeth Chalmers, Jonathan Kell, MD, Joe Hickey, PhD, Clark Paramore, MPH, Minesh Jobanputra, MD, Kate Ryan, MD

Blood (2019) 134 (Supplement_1): 3550.

https://doi.org/10.1182/blood-2019-129930

Published: 2019

Journal Articles

Evaluating the Volumetric Liver Fat Fraction in Patients Referred for Investigation of Hyperferritinemia

Aoife Dervin, MBBS, BSc, MRCP, Perla Eleftheriou, FRCPath, MRCP, Deepak Suri, MBBS FRCP, Sara Trompeter, MBChB BSc MRCPCH FRCPath MSc, Maciej W Garbowski, MD PhD, Tim St. Pierre, John B. Porter, MA MDFRCP FRCPath, Emma Drasar, MBBS MRCP FRCPath PhD

Blood (2019) 134 (Supplement_1): 3539.

https://doi.org/10.1182/blood-2019-128122

Published: 2019

NARROW

Aberrant Responsiveness of Erythropoiesis to Iron Deficiency in Polycythemia Vera

Randomized Controlled Trial of the Efficacy and Safety of Deferiprone in Iron-Overloaded Patients with Sickle Cell Disease or Other Anemias

A Pilot Study of Exjade (Deferasirox) As Monotherapy in Higher Risk MDS or Acute Myeloid Leukemia

Impact of HFE gene Variants on Iron Overload, Overall Survival and Leukemia-Free Survival in Myelodysplastic Syndromes

A Multicenter, Italian Trial of Early Iron Chelation Therapy with Low Dose Deferasirox (Exjade®) in Patients with Low/Intermediate-1 Risk MDS at the Beginning of Transfusional Story

Hematopoietic Stem Cell Transplantation in Βthalassemia Major: The Egyptian Outcome

Understanding the Association between Transfusion Status (TS) and Overall Survival (OS), and Other Clinical Outcomes in Patients with Myelodysplastic Syndromes (MDS) from the Physicians' Perspective: A Pilot Survey

MRI Evaluation of Liver and Cardiac Iron Overload Impact on Hematopoietic Stem Cell Transplantation with β-Thalassemia Major

Prevalence of Iron Deficiency and Iron Deficiency Anemia during Pregnancy: A Single Centre Canadian Study

Risk Factors and Characteristics of CRS in CAR-T Treatment

NTBI Is Transiently Generated from Two Compartments during a Single Dose of Intravenous Iron - a Randomized Controlled Clinical Study

Factor-Associated Risk Factors of Mild Cognitive Impairment in Thalassemia Patients : Probable Role of FGF21

Effects of Luspatercept on Iron Overload and Impact on Responders to Luspatercept: Results from the BELIEVE Trial

Does Gene Therapy in Beta Thalassemia Normalize Novel Markers of Ineffective Erythropoiesis and Iron Homeostasis?

Clinical Outcomes after Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Transfusion-Dependent β-Thalassemia Treated at the Bambino Gesù Children's Hospital, Rome, Italy

Use of Buprenorphine/Naloxone in Ameliorating Acute Care Utilization and Chronic Opioid Use in Adults with Sickle Cell Disease

Treosulfan Metabolite (S, S-EBDM) Pharmacokinetics Influences Regimen Related Toxicity in Patients with Beta Thalassaemia Major Undergoing HSCT

Neurological Adverse Events Following CAR-T Cell Therapy: A Real-World Analysis of Adult Patients Treated with Axicabtagene Ciloleucel or Tisagenlecleucel

Routine Management, Healthcare Resource Use and Patient/Caregiver-Reported Outcomes of Patients with Transfusion-Dependent β-Thalassaemia in the United Kingdom: A Mixed Methods Observational Study

Evaluating the Volumetric Liver Fat Fraction in Patients Referred for Investigation of Hyperferritinemia

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only